Stem cell therapy of heart failure: clinical trials, problems and perspectives


Cite item

Full Text

Abstract

Today cell therapy is considered as a new perspective approach in the treatment of different structural and functional changes in ischemic myocardium. In the present review we analyze last achievements in autologous stem and progenitor cells use for the regeneration of damaged myocardium at postinfarct heart failure, chronic ischemic cardiomyopathy and chronic heart failure.

About the authors

T N Kochegura

A Yu Efimenko

Zh A Akopyan

E E Parfenova

T N Kochegura

Lomonosov Moscow State University, Moscow

Lomonosov Moscow State University, Moscow

A Y Efimenko

Lomonosov Moscow State University, Moscow

Lomonosov Moscow State University, Moscow

Zh A Akopyan

Lomonosov Moscow State University, Moscow

Lomonosov Moscow State University, Moscow

EV M V

Lomonosov Moscow State University, Moscow

Lomonosov Moscow State University, Moscow

References

  1. Беленков Ю.Н., Привалова Е.В., Чекнева И.С. Клеточная терапия в лечении хронической сердечной недостаточности: виды применяемых стволовых клеток, результаты последних клинических исследований. Кардиология и сердечно-сосудистая хирургия 2008; 5: 4-18.
  2. Orlic D. Stem cell repair in ischemic heart disease: an experiment models. Int. J. Hematol. 2002; 76: 144-5.
  3. Orlic D., Kajstura J., Chimentis A. et al. Bone marrow cells regenerate infracted myocardium. Nature 2004; 410: 701-5.
  4. Anversa P. et al. Cardiac regeneration. J. Am. Coll. Cardiol. 2006; 47(9): 1769-76.
  5. Kinnaird Т., Stabile E., Burnett M.S. et al. Marrow-derived stromal cells express genes encoding a broad spectrum arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ. Res. 2004; 94: 25-31.
  6. Трактуев Д.О., Парфенова E.B., Ткачук В.А. и др. Стромальные клетки жировой ткани - пластический тип клеток, обладающих высоким терапевтическим потенциалом. Цитология 2006; 48: 83-94.
  7. Fukuda К. Development of regenerative cardiomyocytes from mesenchymal stem cells for cardiovascular tissue engineering. Artif. Organs. 2001; 25: 187-97.
  8. Lyngbaek S., Scheider M., Hansen J. L. et al. Cardiac regeneration byresident stem and progenitor cells in the adult heart. Basic Res. Cardiol. 2007; 102(2): 101-14.
  9. Terada N., Hamazaki Т., Oka M. et al. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature 2002; 416: 542-5.
  10. Ying Q.L., Nichols J., Evans E.P. et al. Changing potency by spontaneous fusion. Nature 2002; 416: 545-8.
  11. Vassilopoulos G., Wang P.R., Russell D.W. Transplanted bone marrow regenerates liver by cell fusion. Nature 2003; 422: 901-4.
  12. Alvarez-Dolado M., Pardal R., Garcia-Verdugo J. M. et al. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 2003; 425: 968-73.
  13. Ogle B.M., Cascalho M., Piatt J.L. Biological implications of cell fusion. Mol. Cell. Biol. 2005; 6(7): 567-75.
  14. Menasche P. Cell-based therapy for heart disease: a clinically oriented perspective. Molecular therapy 2009; 17(7): 758-66.
  15. Makino S., Fukuda K., Miyoshi S. et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J. Clin. Invest. 1999; 103: 697-705.
  16. Fukuda K., Fujita J. Mesenchymal, but not hematopoietic, stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction in mice. Kidney International 2005; 68: 1940-3
  17. Kajstura J., Rota M., Whang B. et al. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ. Res. 2005; 96: 127-37.
  18. Kawada H., Fujita J., Kinjo K. et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004; 104(12): 3581-7.
  19. Zuk P.A., Zhu M., Ashjian P. et al. Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell. 2002; 13: 4279-95.
  20. Gimble J.M., Katz. A.J., Bunnell B.A. Adipose-derived stem cells for regenerative medicine. Circ. Res. 2007; 100: 1249-60.
  21. van Dijk, Niessen H.W.M., Visser F.C., et al. Differentiation of adipose-derived stem cells toward cardiomyocytes: the role of the extracellular matrix molecules fibronectine and laminin. Proceedings of Fifth Annual Meetings of International Federation of Adipose Therapeutic and Science, Indianapolis 2007: 27-8.
  22. Planat-Benard V., Menard C, Andre M. et al. Spontaneous cardiomyocyte differentiation from adipose tissue stromal cells. Circ. Res. 2004; 94: 223-9.
  23. Perin E.C., Lopez J. Methods of stem cell delivery in cardiac diseases. Nat. Clin. Pract. Cardiovasc. Med. 2006; 3: 110-3.
  24. Charwat S., Gyongyo M., Lang I. et al. Role of adult bone marrow stem cells in the repair of ischemic myocardium. Experimental Hematology 2008; 36: 672-80.
  25. Strauer B. E., Brehm M., Schannwell С. M. The therapeutic potential of stem cells in heart disease. Cell Prolif. 2008; 41: 126-45.
  26. Lipinski M. J., Biondi-Zoccai G.G., Abbate A. et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction. J. Am. Coll. Cardiol. 2007; 50(18): 1761-7.
  27. Takano H., Hasegawa H., Kuwabara Y. et al. Feasibility and safety of granulocyte colonystimulating factor treatment in patients with acute myocardial infarction. Int. J. Cardiol. 2007; 122: 41-7.
  28. Fan L., Chen L., Chen X., et al. A meta-analysis of stem cell mobilization by granulocyte colony-stimulating factor in the treatment of acute myocardial infarction. Cardiovasc. Drugs Ther. 2008; 22: 45-54.
  29. Menasche P. Current status and future prospects for cell transplantation to prevent congestive heart failure. Semin Thorac. Cardiovasc. Surg. 2008; 20: 131-7.
  30. Yao К., Huang R., Qian J. et al. Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function. Heart 2D08; 94: 1147-53.
  31. Kocher A.A., Shuster M.D., Szaboles M.J. et al. Neovasculrization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, redused remodeling and improves cardiac function. Nat. Med. 2001; 7: 430-6.
  32. Strauer B.E., Brehm M., Zeus T. et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J. Am. Coll. Cardiol. 2005; 46: 1651-8.
  33. Assmus В., Fischer-Rasokat U., Honold J. et al. TOPCARE-CHD Registry. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. Circ. Res. 2007; 100: 1234-41.
  34. Allman K.C., Shaw L.J., Hachamovitch R., et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J. Am. Coll. Cardiol. 2002; 39; 7: 1151-58.
  35. Рахмат-Заде T.M., Скридлевская E.A., Акчурин P.С. Костномозговые стволовые клетки в лечении ишемической болезни сердца. Кардиология 2007; 1: 47-51.
  36. Perin Е.С., Dohmann H.F.R., Borojevic R. et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003; 107: 2294-302.
  37. Perin E.C., Dohmann H.F., Borojevic R. et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 2004; 110: 213-8.
  38. Galinanes M., Loubani M., Davies J., et al. Autotransplantation of unmanipulated bone marrow into scarred myocardium is safe and enhances cardiac function in humans. Cell Transplant 2004; 13: 7-13.
  39. Fuchs S., Satler L.F., Kornowski R. et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. J. Am. Coll. Cardiol. 2003; 41: 1721-4.
  40. Tse H.F., Kwong Y.L., Chan J.K. et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003; 361: 47-9.
  41. Silva G.V., Perin E.C., Dohmann H.F.R. et al. Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear cells in patients listed for heart transplantation. J. Tex. Heart Inst. 2004; 31: 214-9.
  42. Assmus В., Honold J., Schachinger V. et al. Transcoronary transplantation of progenitor cells after myocardial infarction. J. N. Engl. Med. 2006; 355: 1222-32.
  43. Beeres S.L., Bax J.J., Kaandorp Т.Д. et al. Usefulness of intramyocardial injection of autologous bone marrow-derived mononuclear cells in patients with severe angina pectoris and stress-induced myocardial ischemia. J. Am. Coll. Cardiol. 2006; 97: 1326-31.
  44. Briguori C, Reimers В., Sarais С et al. Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina. J. Am. Heart. 2006; 151: 674-80.
  45. Kuethe F., Richartz B.M., Kasper С et al. Autologous intracoronary mononuclear bone marrow cell transplantation in chronic ischemic cardiomyopathy in humans. Int. J. Cardiol. 2005; 100: 485-91.
  46. Бокерия Л.А., Бузиашвили Ю. И., Мацкеплишвили С. Т., Камардинов Д. X. Первый опыт применения стволовых клеток костного мозга для регенерационной терапии ишемической болезни сердца. Кардиология и сердечно-сосудистая хирургия 2004; 6: 34-7.
  47. Ахмедов Ш.Д., Бабокин В.Е., Рябов В.В. и др. Клинический опыт применения аутологичных мононуклеарных клеток костного мозга в лечении пациентов с ишемической болезнью сердца и дилатационной кардиомиопатией. Кардиология 2006; 7:10-14.
  48. Hendrikx М., Hensen К., Clijsters С. et al. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation 2006; 114: 101-7.
  49. Stamm C, Nasseri В., Drews Т., et al. Cardiac cell therapy: A realistic concept for elderly patients. Experimental Gerontology 2008; 43: 679-90.
  50. Losordo D.W., Schatz R.A., White C.J. et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase l/lla double-blind, randomized controlled trial. Circulation 2007; 115: 3165-72.
  51. Stamm C, Kleine H., Choi Y. et al. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: Safety and efficacy studies. J. Thorac. Cardiovasc. Surg. 2007; 133: 717-25.
  52. Fuchs S., Kornowski R., Weisz G. et al. Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. J. Am. Coll. Cardiol. 2006; 97(6): 823-9.
  53. Patel A.N., Geffner L, Vina R.F. et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. J. Thorac. Cardiovasc. Surg. 2005; 130(6): 1631-8.
  54. Ozbaran M., Omay S.B., Nalbantgil S. et al. Autologous peripheral stem cell transplantation in patients with congestive heart failure due to ischemic heart disease. Eur. J. Cardiothorac. Surg. 2004; 25: 342-50.
  55. Pittenger M.F., Martin B.J. Mesenchymal stem cells and their potential as cardiac theurapetics. Circ. Res. 2004; 95: 9-20.
  56. Цыб А.Ф., Конопляников А.Г., Каплан M.A. и др. Использование системной трансплантации кардиомиобластов, полученных из мезенхимальных стволовых клеток аутологичного костного мозга, при комплексной терапии больных с хронической сердечной недостаточностью. Клеточная трансплантология и тканевая инженерия 2008; 1: 78-84.
  57. Шумаков В.И., Казаков Э.Н., Онищенко Н.А. и др. Первый опыт клинического применения аутологичных мезенхимальных стволовых клеток костного мозга для восстановления сократительной функции миокарда. Рос. кардиол. журн. 2003; 5(43): 42-50.
  58. Breitbach М., Bostani Т., Roell W. et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007; 110: 1362-9.
  59. Pouzet В., Volquin J.Т., Hagege A.A. et al. Factors affecting functional outcome after autologous skeletal myoblast transplantation. Ann. Thorac. Surg. 2001; 71: 844-51.
  60. Tambara K., Sakakibara Y., Sakaguchi G. et al. Transplanted skeletal myoblasts can fully replace the infarcted myocardium when they survive in the host in large numbers. Circulation 2003; 108: 259-63.
  61. Reinecke H., Poppa V., Murry C.E. Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. J. Mol. Cell Cardiol. 2002; 34: 241-9.
  62. Menasche P., Hagege A.A., Scorsin M. et al. Myoblast transplantation for heart failure. Lancet 2001; 357: 279-80.
  63. Siminiak Т., Kalawski R., Fiszer D. et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: phase I clinical study with 12 months of follow-up. J. Am. Heart. 2004; 148: 531-7.
  64. Dib N., Michler R.E., Pagani F.D. et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation 2005; 112: 1748-55.
  65. Menasche P., Alfieri 0., Janssens S. et al. The myoblast autologous grafting in ischemic cardiomyopathy [MAGIC) trial. First randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117: 1189-200.
  66. Fedak P.W.M. Paracrine effects of cell transplantation: modifying ventricular remodeling in the failing heart. Semin. Thorac. Cardiovasc. Surg. 2008; 20: 87-93.
  67. Ince H., Petzsch M., RehdersT.C. etal.Transcatheter transplantation of autologous skeletal myoblasts in postinfarction patients with severe left ventricular dysfunction. J. Endovasc. Ther. 2004; 11: 695-704.
  68. Biagini E., Valgimigli M., Smits P.С et al. Stress and tissue Doppler echocardiographic evidence of effectiveness of myoblast transplantation in patients with ischemic heart failure. Eur. J. Heart Fail. 2006; 8: 641-8.
  69. Dib N., Dinsmore J., Mozak R. et al. Safety and feasibility of percutaneous autologous skeletal myoblast transplantation for ischemic cardiomyopathy: Six-month interim analysis. Circulation 2006; 114: 88.
  70. Dimmeler S., Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ. Res. 2008; 102: 1319-30.
  71. Rossi D.J., Jamieson C.H., Weissman I.L. Stems cells and the pathways to aging and cancer. Cell 2008; 132: 681-96.
  72. Hofmann M., Wollert K.C., Meyer G.P. et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005; 111: 2198-202.
  73. Freyman Т., Polin G., Osman H., et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur. Heart J. 2006; 27: 1114-22.
  74. Hou D., Youssef E.A., Brinton T.J. et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 2005; 112: 1150-6.
  75. Anversa P., Kajstura J., Leri A. et al. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation 2006; 113: 1451-63.
  76. Messina E., De Angelis L., Frati G. et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res. 2004; 95(9): 911-21.
  77. Leri A., Kajstura J., Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol. Rev. 2005; 85: 1373-416.
  78. Smith R.R., Barile L, Cho H.C. et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007; 115: 896-908.
  79. Takahashi K., Tanabe K., Ohnuki M. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131: 861-872.
  80. Yu J., Vodyanik M.A., Smuga-Otto K. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-20.
  81. Zhou H., Wu S., Joo J.Y. et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem 2009; 4: 381-4.

Copyright (c) 2010 PJSC Human Stem Cells Institute


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 57156 от 11.03.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies